What Lies Ahead For Sarepta Therapeutics, Inc.?

Sarepta Therapeutics (NASDAQ: SRPT  ) has been one roller coaster of a stock over the last year while waiting for the Food and Drug Administration to make up its mind about whether its Duchenne muscular dystrophy drug, eteplirsen, deserves an accelerated approval.

In November, Sarepta fell sharply after the biotech told investors that the FDA wasn't sure Sarepta had enough data to justify an accelerated approval. It appears the phase 3 failure of Prosensa (NASDAQ: RNA  ) and GlaxoSmithKline's (NYSE: GSK  ) Duchenne muscular dystrophy drug, drisapersen, influenced the FDA's decision.

In the video below, Fool contributor Brian Orelli and health-care bureau chief Max Macaluso discuss Sarepta's current predicament and give some advice on how investors should think about the long-term prospects of the company.

Looking for hyper growth?
Learn about Fool co-founder David Gardner's scientific approach to crushing the market and six carefully chosen picks for ultimate growth instantly. Just click here now for access to the free premium report.


Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2876539, ~/Articles/ArticleHandler.aspx, 12/20/2014 3:25:52 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement